Sinonasal Squamous Cell Carcinoma Survival Outcomes Following Induction Chemotherapy vs Standard of Care Therapy

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Murr, A.T.
    • Affiliation: School of Medicine, Department of Otolaryngology/Head and Neck Surgery
  • Lenze, N.R.
    • Affiliation: School of Medicine, Department of Otolaryngology/Head and Neck Surgery
  • Weiss, J.M.
    • Affiliation: School of Medicine, Department of Medicine
  • Grilley-Olson, J.E.
    • Affiliation: School of Medicine, Department of Medicine
  • Patel, S.A.
    • Affiliation: School of Medicine, Department of Medicine
  • Shen, C.
    • Other Affiliation: Department of Radiation Oncology
  • Chera, B.S.
    • Affiliation: School of Medicine, Department of Radiation Oncology
  • Zanation, A.M.
    • Affiliation: School of Medicine, Department of Otolaryngology/Head and Neck Surgery
  • Thorp, B.D.
    • Affiliation: School of Medicine, Department of Otolaryngology/Head and Neck Surgery
  • Sheth, S.H.
    • Affiliation: School of Medicine, Department of Medicine
Abstract
  • Objective To compare oncologic outcomes in sinonasal squamous cell carcinoma (SNSCC) treated with standard of care (SOC) definitive therapy, consisting of surgery or chemoradiotherapy, vs induction therapy followed by definitive therapy. Study Design Retrospective review.SettingAcademic tertiary care hospital. Methods The medical records of patients with biopsy-proven SNSCC treated between 2000 and 2020 were reviewed for demographics, tumor characteristics, staging, treatment details, and oncologic outcomes. Patients were matched 1-to-1 by age, sex, and cancer stage according to treatment received. Time-to-event analyses were conducted. Results The analysis included 26 patients with locally advanced SNSCC who received either induction therapy (n = 13) or SOC (n = 13). Baseline demographics, Charlson Comorbidity Index, and median follow-up time were well balanced. Weekly cetuximab, carboplatin, and paclitaxel were the most common induction regimen utilized. Tolerance and safety to induction were excellent. Objective responses were observed in 11 of 13 patients receiving induction. No difference in disease-free survival was found between the induction and SOC groups at 1 or 3 years. However, when compared with SOC, induction therapy resulted in significant improvement in overall survival at 2 years (100% vs 65.3%, P = .043) and 3 years (100% vs 48.4%, P = .016) following completion of definitive therapy. Two patients in the SOC group developed metastatic disease, as compared with none in the induction group. Conclusions Induction therapy was safe and effective. When compared with SOC, induction therapy improved 3-year overall survival.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Otolaryngology–Head and Neck Surgery
Journal volume
  • 167
Journal issue
  • 5
Page start
  • 846
Page end
  • 851
Language
  • English
Version
  • Publisher
ISSN
  • 0194-5998
Publisher
  • SAGE Publications Ltd

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 01945998221083097.pdf 2023-01-12 Public Download